Fig 1.
B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; TE, treatment-experienced; TN, treatment-naïve.
Table 1.
Baseline demographics and disease characteristics by ART status.
Fig 2.
Virologic outcomes at 3, 6, and 12 months (M = E analysis).
(A) TN and (B) TE participants. At 12 months, of the 26 participants with no virologic data, 1 TN participant discontinued B/F/TAF before the 12-month time window (but remained in the study), 7 (6 TN and 1 TE) participants withdrew from the study before the 12-month time window (but remained on B/F/TAF), 1 TN participant discontinued B/F/TAF and withdrew from the study before the 12-month time window and 17 (10 TN and 7 TE) remained on B/F/TAF before the 12-month time window and had their last visit ≥275 days from B/F/TAF initiation. M = E, missing-as-excluded; TE, treatment-experienced; TN, treatment-naïve.
Fig 3.
Change in CD4 count in (A) TN and (B) TE participants and change in CD4/CD8 ratio in (C) TN and (D) TE participants from baseline to 12 months.
a In participants with data available at baseline and at 12 months. b p-values calculated using the Signed Rank test. c p-values calculated using the Sign test. CD, cluster of differentiation; M, months; Q, quartile; TE, treatment-experienced; TN, treatment-naïve.
Table 2.
Adverse events reported through 12 months overall and by ART status.
Fig 4.
Change in weight in (A) TN and (B) TE participants and change in BMI in (C) TN and (D) TE participants from baseline to 12 monthsa.
a In participants with data available at baseline and 12 months. b p-values calculated using the Sign test. BMI, body mass index; M, months; Q, quartile; TE, treatment-experienced; TN, treatment-naïve.
Fig 5.
Changes in lipid levels from baseline to 12 months in (A) TN and (B) TE participantsa.
a In participants with data available at baseline and 12 months. b p-values calculated using the Student t-test. c p-values calculated using the Sign test. HDL, high-density lipoprotein; LDL, low-density lipoprotein; Q, quartile; TE, treatment-experienced; TN, treatment-naïve.
Fig 6.
Change in eGFR levels from baseline to 12 months in (A) TN and (B) TE participants.
p-values calculated using the Sign test. eGFR, estimated glomerular filtration rate; Q, quartile; TE, treatment-experienced; TN, treatment-naïve.